Carclo (CAR LN) Trading in line | Greene King (GNK LN) Upcoming Q1 update unlikely to be a positive ST catalyst | Horizon Discovery Group (HZD LN) Collaboration with Redx Pharma | Lookers (LOOK LN) Benfield acquisition for £87.5m – 12.5% upgrades in 1st full year (FY’16) | Redde (REDD LN) Upgrading PBT, strong growth drives dividend | Summit Therapeutics (SUMM LN) Dr Ralf Rosskamp appointed Chief Medical Officer
![working](/images/WorkingLarge.gif)
03 Sep 2015
Morning Song
Carclo plc (CAR:LON), 30.7 | Greene King (GNK:LON), 0 | ZIGUP PLC (21W:FRA), 0 | Summit Therapeutics Inc (SMMT:NAS), 0
![](/images/orange-lock.png)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Song
Carclo plc (CAR:LON), 30.7 | Greene King (GNK:LON), 0 | ZIGUP PLC (21W:FRA), 0 | Summit Therapeutics Inc (SMMT:NAS), 0
- Published:
03 Sep 2015 -
Author:
Singer CM Team -
Pages:
15 -
Carclo (CAR LN) Trading in line | Greene King (GNK LN) Upcoming Q1 update unlikely to be a positive ST catalyst | Horizon Discovery Group (HZD LN) Collaboration with Redx Pharma | Lookers (LOOK LN) Benfield acquisition for £87.5m – 12.5% upgrades in 1st full year (FY’16) | Redde (REDD LN) Upgrading PBT, strong growth drives dividend | Summit Therapeutics (SUMM LN) Dr Ralf Rosskamp appointed Chief Medical Officer